2022年系统性红斑狼疮研究新进展

doi:10.35541/cjd.20220924

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (3): 266-269.doi: 10.35541/cjd.20220924

2022年系统性红斑狼疮研究新进展

罗帅寒天¹ 龙海¹ 陆前进^1，2，3

¹中南大学湘雅二医院皮肤性病科，长沙 410011；²中国医学科学院、北京协和医学院皮肤病医院皮肤科，南京 210042；³中国医学科学院免疫性皮肤病基础与转化研究重点实验室，南京 210042

收稿日期:2022-12-29 修回日期:2023-02-07 发布日期:2023-03-06
通讯作者: 陆前进 E-mail:qianlu5860@pumcderm.cams.cn
基金资助:
国家自然科学基金（81703133、82273540、81830097）；湖南省自然科学基金（2021JJ40856）；湖南省科技创新计划项目（2018RS3031）；长沙市科技计划项目（KQ1802002）；中国医学科学院中央级公益性科研院所基本科研业务费专项资金（2021-RC320-001、2020-RC320-003）；中国医学科学院医学与健康科技创新工程项目（2021-I2M-1-059）

Research advances in systemic lupus erythematosus in 2022

Luo Shuaihantian¹, Long Hai¹, Lu Qianjin^1,2,3

¹Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha 410011, China; ²Department of Dermatology, Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China; ³Key Laboratory of Immunological Dermatology and Translational Research, Chinese Academy of Medical Sciences, Nanjing 210042, China

Received:2022-12-29 Revised:2023-02-07 Published:2023-03-06
Contact: Lu Qianjin E-mail:qianlu5860@pumcderm.cams.cn
Supported by:
National Natural Science Foundation of China （81703133, 82273540, 81830097）; Natural Science Foundation of Hunan Province of China （2021JJ40856）; Hunan Science and Technology Innovation Project （2018RS3031）; Changsha Science and Technology Planning Project （KQ1802002）; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences （2021-RC320-001, 2020-RC320-003）; CAMS Innovation Fund for Medical Sciences （2021-I2M-1-059）

摘要/Abstract

摘要： 【摘要】系统性红斑狼疮一直是国内外的研究热点。2022年国内外研究者通过对其流行病学、发病机制、诊断和评估、治疗方案等方面的研究，取得了一系列重要成果，本文主要综述代表性成果。

关键词: 红斑狼疮, 系统性, 诊断, 治疗, 发病率, 患病率, 生物制剂, 生物标志物

Abstract: 【Abstract】 Systemic lupus erythematosus has always been a research hotspot in the field of autoimmune diseases in China and other countries. In 2022, Chinese and international researchers have made a lot of new progress in epidemiology, pathogenesis, diagnosis and evaluation, and treatment of systemic lupus erythematosus. This review mainly summarizes major representative advances.

Key words: Lupus erythematosus, systemic, Diagnosis, Therapy, Incidence, Prevalence, Biological Agents, Biomarker

罗帅寒天龙海陆前进. 2022年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2023,56(3):266-269. doi:10.35541/cjd.20220924

Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2022[J]. Chinese Journal of Dermatology, 2023, 56(3): 266-269.doi:10.35541/cjd.20220924

参考文献 29

［1］	Tian J, Zhang D, Yao X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study［J］. Ann Rheum Dis, 2023,82（3）:351⁃356. doi: 10.1136/ard⁃2022⁃223035.
［2］	Jenks SA, Cashman KS, Zumaquero E, et al. Distinct effector B cells induced by unregulated Toll⁃like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus［J］. Immunity, 2018,49（4）:725⁃739.e6. doi: 10.1016/j.immuni.2018. 08.015.
［3］	Brown GJ, Cañete PF, Wang H, et al. TLR7 gain⁃of⁃function genetic variation causes human lupus［J］. Nature, 2022,605（7909）:349⁃356. doi: 10.1038/s41586⁃022⁃04642⁃z.
［4］	Wu HJ, Ivanov II, Darce J, et al. Gut⁃residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells［J］. Immunity, 2010,32（6）:815⁃827. doi: 10.1016/j.immuni. 2010.06.001.
［5］	Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria［J］. Cell, 2009,139（3）:485⁃498. doi: 10.1016/j.cell.2009.09.033.
［6］	Flannigan KL, Denning TL. Segmented filamentous bacteria⁃induced immune responses: a balancing act between host protection and autoimmunity［J］. Immunology, 2018,154（4）:537⁃546. doi: 10.1111/imm.12950.
［7］	Valiente GR, Munir A, Hart ML, et al. Gut dysbiosis is associated with acceleration of lupus nephritis［J］. Sci Rep, 2022,12（1）:152. doi: 10.1038/s41598⁃021⁃03886⁃5.
［8］	van Drongelen V, Scavuzzi BM, Nogueira SV, et al. HLA⁃DRB1 allelic epitopes that associate with autoimmune disease risk or protection activate reciprocal macrophage polarization［J］. Sci Rep, 2021,11（1）:2599. doi: 10.1038/s41598⁃021⁃82195⁃3.
［9］	Wang YF, Zhang Y, Lin Z, et al. Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups［J］. Nat Commun, 2021,12（1）:772. doi: 10.1038/s41467⁃021⁃21049⁃y.
［10］	Miglioranza Scavuzzi B, van Drongelen V, Kaur B, et al. The lupus susceptibility allele DRB1*03:01 encodes a disease⁃driving epitope［J］. Commun Biol, 2022,5（1）:751. doi: 10.1038/s42003⁃022⁃03717⁃x.
［11］	Pilsczek FH, Salina D, Poon KK, et al. A novel mechanism of rapid nuclear neutrophil extracellular trap formation in response to Staphylococcus aureus［J］. J Immunol, 2010,185（12）:7413⁃7425. doi: 10.4049/jimmunol.1000675.
［12］	Denny MF, Yalavarthi S, Zhao W, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs［J］. J Immunol, 2010,184（6）:3284⁃3297. doi: 10. 4049/jimmunol.0902199.
［13］	Monteith AJ, Miller JM, Williams JM, et al. Altered mitochondrial homeostasis during systemic lupus erythematosus impairs neutrophil extracellular trap formation rendering neutrophils ineffective at combating Staphylococcus aureus［J］. J Immunol, 2022,208（2）:454⁃463. doi: 10.4049/jimmunol.210 0752.
［14］	Biazar C, Sigges J, Patsinakidis N, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus （EUSCLE）［J］. Autoimmun Rev, 2013,12（3）:444⁃454. doi: 10.1016/j.autrev.2012.08.019.
［15］	Fernandes⁃Alnemri T, Yu JW, Datta P, et al. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA［J］. Nature, 2009,458（7237）:509⁃513. doi: 10.1038/nature07710.
［16］	Zhao Z, Zhu H, Li Q, et al. Skin CD4+ Trm cells distinguish acute cutaneous lupus erythematosus from localized discoid lupus erythematosus/subacute cutaneous lupus erythematosus and other skin diseases［J］. J Autoimmun, 2022,128:102811. doi: 10.1016/j.jaut.2022.102811.
［17］	Kang HM, Subramaniam M, Targ S, et al. Multiplexed droplet single⁃cell RNA⁃sequencing using natural genetic variation［J］. Nat Biotechnol, 2018,36（1）:89⁃94. doi: 10.1038/nbt.4042.
［18］	Perez RK, Gordon MG, Subramaniam M, et al. Single⁃cell RNA⁃seq reveals cell type⁃specific molecular and genetic associations to lupus［J］. Science, 2022,376（6589）:eabf1970. doi: 10.1126/science.abf1970.
［19］	Heba AC, Toupance S, Arnone D, et al. Telomeres: new players in immune⁃mediated inflammatory diseases?［J］. J Autoimmun, 2021,123:102699. doi: 10.1016/j.jaut.2021.102699.
［20］	Haque S, Rakieh C, Marriage F, et al. Shortened telomere length in patients with systemic lupus erythematosus［J］. Arthritis Rheum, 2013,65（5）:1319⁃1323. doi: 10.1002/art.37895.
［21］	Wang XF, Xu WJ, Wang FF, et al. Telomere length and development of systemic lupus erythematosus: a mendelian randomization study［J］. Arthritis Rheumatol, 2022,74（12）:1984⁃1990. doi: 10.1002/art.42304.
［22］	Apte M, McGwin G Jr, Vilá LM, et al. Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort （LV）. ［corrected］［J］. Rheumatology （Oxford）, 2008,47（3）:362⁃367. doi: 10.1093/rheumatology/kem371.
［23］	Yafasova A, Fosbøl EL, Schou M, et al. Long⁃term cardiovascular outcomes in systemic lupus erythematosus［J］. J Am Coll Cardiol, 2021,77（14）:1717⁃1727. doi: 10.1016/j.jacc.2021.02.029.
［24］	Myhr KA, Zinglersen AH, Hermansen MF, et al. Left ventricular size and function in patients with systemic lupus erythematosus associate with lupus anticoagulant: an echocardiographic follow⁃up study［J］. J Autoimmun, 2022,132:102884. doi: 10.1016/j.jaut.2022.102884.
［25］	Weber BN, Stevens E, Barrett L, et al. Coronary microvascular dysfunction in systemic lupus erythematosus［J］. J Am Heart Assoc, 2021,10（13）:e018555. doi: 10.1161/JAHA.120.018555.
［26］	Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti⁃BDCA2 antibody litifilimab for systemic lupus erythematosus［J］. N Engl J Med, 2022,387（10）:894⁃904. doi: 10.1056/NEJ Moa2118025.
［27］	Lé AM, Puig L, Torres T. Deucravacitinib for the treatment of psoriatic disease［J］. Am J Clin Dermatol, 2022,23（6）:813⁃822. doi: 10.1007/s40257⁃022⁃00720⁃0.
［28］	Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double⁃blind, placebo⁃controlled trial［J］. Arthritis Rheumatol, 2023,75（2）:242⁃252. doi: 10.1002/art.42391.
［29］	Dunford P, Comer G, Raymond R, et al. PREVAIL 1: a multiple ascending dose study in normal healthy volunteers of PRV⁃3279, a novel bispecific DART molecule targeting CD32B and CD79B on B cells, with potential for treatment of SLE［J］. Arthritis Rheumatol, 2020,72 （suppl 10）:1701⁃1703.

[1]	中华医学会皮肤性病学分会免疫学组. [开放获取] 中国慢性诱导性荨麻疹诊治专家共识（2023）[J]. 中华皮肤科杂志, 2023, 0(4): 20220819-e20220819.
[2]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 慢性自发性荨麻疹达标治疗专家共识（2023）[J]. 中华皮肤科杂志, 2023, 0(4): 20230004-e20230004.
[3]	中华医学会皮肤性病学分会银屑病专业委员会. 银屑病生物制剂达标治疗专家共识[J]. 中华皮肤科杂志, 2023, 56(3): 191-203.
[4]	周健俞晨王刚. 司库奇尤单抗治疗13例难治性局限性脓疱型银屑病的临床疗效与安全性观察[J]. 中华皮肤科杂志, 2023, 56(3): 247-251.
[5]	胡琨杨晶王巧林陈军臣张谧朱武张斌窦冠珅 Wendong Chen, 匡叶红. [开放获取] 依奇珠单抗治疗银屑病短期疗效的单中心病例回顾性研究[J]. 中华皮肤科杂志, 2023, 56(3): 210-215.
[6]	万立胡彬罗红玉方美珍韩丽娟陈强周小勇陈柳青陈金波. 天疱疮或大疱性类天疱疮合并单纯疱疹病毒感染8例临床特征及治疗分析[J]. 中华皮肤科杂志, 2023, 56(3): 229-233.
[7]	陈奇权杨显杰顾恒徐金华郝飞姚煦宋志强. [开放获取] 基于德尔菲法构建《中国慢性诱导性荨麻疹专家诊治共识（2023）》[J]. 中华皮肤科杂志, 2023, 0(3): 20220814-e20220814.
[8]	洪芷榆谢红付李吉黄莹雪. 发光二极管红黄光治疗急性发作期面部炎症性皮肤病的支付意愿分析[J]. 中华皮肤科杂志, 2023, 0(3): 20220128-e20220128.
[9]	任芬芬王鹏张景展康晓静. 基于网络药理学预测中药在抗卡波西肉瘤血管生成治疗中的潜在有效成分及分子作用机制[J]. 中华皮肤科杂志, 2023, 0(3): 20220140-e20220140.
[10]	张红燕李丽王明霞董银卯孟宏易帆. 益生菌在痤疮治疗中的应用进展[J]. 中华皮肤科杂志, 2023, 56(3): 283-285.
[11]	何谐栗玉珍. 靶向JAK-STAT信号通路治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(3): 273-278.
[12]	苑辰闫言王宝玺. 反常性痤疮的生物治疗进展[J]. 中华皮肤科杂志, 2023, 56(3): 270-273.
[13]	杨琦郑捷. 生物制剂治疗对银屑病相关心血管疾病的影响[J]. 中华皮肤科杂志, 2023, 56(2): 165-169.
[14]	孙静徐英男林彤薛劲松. 重度玫瑰痤疮眼型28例眼部损害临床治疗结局分析[J]. 中华皮肤科杂志, 2023, 56(2): 142-145.
[15]	杨骥徐欣植李明. 皮肌炎的早期诊断和内脏损伤早期识别[J]. 中华皮肤科杂志, 2023, 56(2): 161-164.

2022年系统性红斑狼疮研究新进展

Research advances in systemic lupus erythematosus in 2022

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 15

Metrics

本文评价

推荐阅读 10